Background: Retrospective analysis to investigate the relationship between the flow-metabolic phenotype and overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) and its potential clinical utility.
Methods: Patients with histopathologically proven PDAC between 2005 and 2014 using tumor attenuation on routine pre-operative CECT as a surrogate for the vascularity and [F]FDG-uptake as a surrogate for metabolic activity on [F]FDG-PET.
Results: In total, 93 patients (50 male, 43 female, median age 63) were included. Hypoattenuating PDAC with high [F]FDG-uptake has the poorest prognosis (median OS 7 ± 1 months), compared to hypoattenuating PDAC with low [F]FDG-uptake (median OS 11 ± 3 months; p = 0.176), iso- or hyperattenuating PDAC with high [F]FDG-uptake (median OS 15 ± 5 months; p = 0.004) and iso- or hyperattenuating PDAC with low [F]FDG-uptake (median OS 23 ± 4 months; p = 0.035). In multivariate analysis, surgery combined with tumor differentiation, tumor stage, systemic therapy and flow metabolic phenotype remained independent predictors for overall survival.
Discussion: The novel qualitative flow-metabolic phenotype of PDAC using a combination of CECT and [F]FDG-PET features, predicted significantly worse survival for hypoattenuating-high uptake pancreatic cancers compared to the other phenotypes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hpb.2023.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]FDG PET/CT Radiomics in Cervical Cancer: A Systematic Review.
Diagnostics (Basel)
December 2024
CReSTIC, UR 3804, Université de Reims Champagne-Ardenne, 51687 Reims, France.
: Cervical cancer is a significant global health concern, with high incidence and mortality rates, especially in less-developed regions. [F]FDG PET/CT is now indicated at various stages of management, but its analysis is essentially based on SUVmax, a measure of [F]FDG uptake. Radiomics, by extracting a multitude of parameters, promises to improve the diagnostic and prognostic performance of the examination.
View Article and Find Full Text PDFIs there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?
World J Surg Oncol
December 2024
Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey.
Purpose: Although 18 F-FDG-PET/CT is helpful in defining many types of cancer, localized prostate cancer should not be treated with this technique. This study describes the use of multi-parametric MRI (mpMRI) to characterize incidental 18 F-FDG uptake in the prostate.
Methods And Materials: While 18 F-FDG-PET/CT is useful for characterizing a variety of cancers, it is not advised for prostate cancer that is localized.
Relationship between [F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer.
Eur Radiol
November 2024
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Aim: Given that claudin 18.2 (CLDN18.2) is a cell surface protein specifically expressed by gastric cancer cells, anti-CLDN18.
View Article and Find Full Text PDFA novel method in myocardial injury risk stratification using intravenous fat emulsion as sole rapid preparation for unfasted patients to suppress myocardial 18F-fluorodeoxyglucose uptake for optimal cardiac PET imaging: a proof-of-concept randomized-crossover trial.
Front Nucl Med
October 2024
Department of Anaesthesia, Perioperative and Pain Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Objectives: Optimal imaging of ischemic or inflammed myocardium via F-FDG PET imaging requires suppression of background carbohydrate metabolism in normal myocardium. Sole administration of intravenous lipid emulsion has not previously been used to rapidly prepare unfasted patients, such as in emergent clinical situations. In this proof-of-concept pilot, we posited that intravenous fat emulsion suppresses physiological metabolic uptake of in non-ischemic, non-inflammatory myocardium in unprepared and unfasted setting for enhanced cardiac positron emission tomography (PET) imaging.
View Article and Find Full Text PDF[Clinical Value of Dual Tracer PET Imaging With Ga-PSMA and F-FDG in Patients With Metastatic Prostate Cancer].
Sichuan Da Xue Xue Bao Yi Xue Ban
September 2024
（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective: In this study, we retrospectively analyzed the imaging characteristics of dual-tracer Ga-prostate specific membrane antigen (PSMA) and F-flurodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in metastatic prostate cancer (mPCa) patients. We analyzed the uptake modes of the dual tracers, explored clinical pathological parameters affecting the F-FDG uptake in the lesions, and evaluated their prognostic implications for prostate specific antigen progression-free survival (PSA-PFS).
Methods: A total of 41 mPCa patients who underwent dual-tracer PET/CT (Ga-PSMA and F-FDG) scans between September 2021 and January 2024 were retrospectively enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!